You are here

  • Home
  • Archive
  • Volume 20, Issue 5
  • Relationship Between ABCF2 Expression and Response to Chemotherapy or Prognosis in Clear Cell Adenocarcinoma of the Ovary

Article Text

Article menu
Download PDFPDF
Ovarian Cancer
Relationship Between ABCF2 Expression and Response to Chemotherapy or Prognosis in Clear Cell Adenocarcinoma of the Ovary
  1. Hiroshi Tsuda, MD, PhD*,†,
  2. Kiyoshi Ito, MD, PhD‡,
  3. Nobuo Yaegashi, MD, PhD‡,
  4. Akira Hirasawa, MD, PhD*,
  5. Tamotsu Sudo, MD, PhD§,
  6. Tsunekazu Kita, MD, PhD∥,
  7. Yoshito Terai, MD, PhD,
  8. Junzo Kigawa, MD, PhD**,
  9. Toru Sugiyama, MD, PhD†,‡ and
  10. Daisuke Aoki, MD, PhD*
  1. * Department of Obstetrics and Gynecology, School of Medicine, Keio University, Tokyo;
  2. † Department of Obstetrics and Gynecology, Osaka City General Hospital, Osaka;
  3. ‡ Department of Obstetrics and Gynecology, Tohoku University Graduate School of Medicine, Sendai;
  4. § Department of Clinical Research, Hyogo Cancer Center, Akashi;
  5. ∥ Department of Obstetrics and Gynecology, National Defense Medical College, Tokorozawa;
  6. Department of Obstetrics and Gynecology, Osaka Medical College, Takatsuki;
  7. ** Department of Obstetrics and Gynecology, Tottori University, Yonago; and
  8. †† Department of Obstetrics and Gynecology, Iwate Medical University, Morioka, Japan.
  1. Address correspondence and reprint requests to Hiroshi Tsuda, MD, PhD, Department of Obstetrics and Gynecology, School of Medicine, Keio University, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan. E-mail: htsud{at}sc.ict.keio.ac.jp.

Abstract

Objectives: The purpose of this study was to evaluate the association of ABCF2 (adenosine triphosphate-binding cassette superfamily F2) protein expression with response to chemotherapy and prognosis in patients with clear cell adenocarcinoma (CCC) of the ovary.

Methods: One hundred sixty-five patients with CCC were studied, and cytoplasmic ABCF2 expression was detected by immunohistochemical staining. All patients underwent platinum-based primary chemotherapy followed by primary surgery.

Results: Adenosine triphosphate-binding cassette superfamily F2 expression was detected in 118 (71.5%) of 165 patients and was not related to age or clinical stage. The response rate to chemotherapy in 38 patients with measurable disease was 47.3% (18/38). The response rate tended to be higher in patients without ABCF2 expression than in those with ABCF2 expression; however, this difference was not significant (66.7% vs 34.8%, P = 0.096). There was no significant difference in overall survival between ABCF2-positive and ABCF2-negative cases (median survival time, 1175 vs 1257 days; P = 0.24).

Conclusions: Adenosine triphosphate-binding cassette superfamily F2 protein was highly expressed in CCC of the ovary, but expression was not related to age, clinical stage, chemoresponse, or prognosis.

  • ABC transporter
  • Clear cell adenocarcinoma
  • Prognosis

https://doi.org/10.1111/IGC.0b013e3181a835fc

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.